亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

医学 卡铂 贝伐单抗 内科学 肿瘤科 彭布罗利珠单抗 人口 放化疗 培美曲塞 化疗 实体瘤疗效评价标准 癌症 外科 顺铂 临床研究阶段 免疫疗法 环境卫生
作者
Krishnansu S. Tewari,Nicoletta Colombo,Bradley J. Monk,Coraline Dubot,M. Valeria Cáceres,Kosei Hasegawa,Ronnie Shapira‐Frommer,Pamela Salman,Eduardo Yáñez,Mahmut Gümüş,Mivael Olivera Hurtado de Mendoza,Vanessa Samouëlian,Vincent Castonguay,Alexander Arkhipov,Cumhur Tekin,Kan Li,Sarper Toker,Stephen J. O’Keefe,Domenica Lorusso
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:10 (2): 185-185 被引量:55
标识
DOI:10.1001/jamaoncol.2023.5410
摘要

Importance: The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. Treatment effects in patient subgroups of the study population are unknown. Objective: To assess efficacy outcomes in patient subgroups of KEYNOTE-826. Design, Setting, and Participants: Exploratory subgroup analyses were conducted in a global, phase 3, randomized, double-blind, placebo-controlled clinical trial. Participants included women with persistent, recurrent, or metastatic adenocarcinoma, adenosquamous carcinoma, or squamous cell carcinoma of the cervix that had not been treated with systemic chemotherapy and was not amenable to curative treatment. This subanalysis was conducted from November 20, 2018, to May 3, 2021. Interventions: Pembrolizumab, 200 mg, every 3 weeks or placebo for up to 35 cycles plus chemotherapy (paclitaxel, 175 mg/m2, plus cisplatin, 50 mg/m2, or carboplatin AUC 5 [area under the free carboplatin plasma concentration vs time curve]) with or without bevacizumab, 15 mg/kg. Main Outcomes and Measures: Overall survival (OS) and progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors version 1.1 in subgroups defined by use of bevacizumab (yes or no), choice of platinum (carboplatin or cisplatin), prior chemoradiotherapy (CRT) exposure only (yes or no), and histologic type (squamous or nonsquamous) in patients with programmed cell death ligand 1-positive tumors (defined as a combined positive score [CPS] ≥1) and in the intention-to-treat population. Results: A total of 617 patients (median age, 51 years; range, 22-82 years) were enrolled in the trial. In the CPS greater than or equal to 1 population, hazard ratios (HRs) for OS favored the pembrolizumab group in all subgroups: with bevacizumab (HR, 0.62; 95% CI, 0.45-0.87) and without bevacizumab (HR, 0.67; 95% CI, 0.47-0.96), use of carboplatin (HR, 0.65; 95% CI, 0.50-0.85) and cisplatin (HR, 0.53; 95% CI, 0.27-1.04), with prior CRT only (HR, 0.56; 95% CI, 0.39-0.81) and without prior CRT only (HR, 0.72; 95% CI, 0.52-1.00), and squamous (HR, 0.60; 95% CI, 0.46-0.79) and nonsquamous (HR, 0.70; 95% CI, 0.41-1.20) histologic type. In the intention-to-treat population, HRs for OS also favored the pembrolizumab group in all subgroups: with bevacizumab (HR, 0.63; 95% CI, 0.47-0.87) and without bevacizumab (HR, 0.74; 95% CI, 0.53-1.04), use of carboplatin (HR, 0.69; 95% CI, 0.54-0.89) or cisplatin (HR, 0.59; 95% CI, 0.32-1.09), with prior CRT only (HR, 0.64; 95% CI, 0.45-0.91) and without prior CRT only (HR, 0.71; 95% CI, 0.53-0.97), and squamous (HR, 0.61; 95% CI, 0.47-0.80) and nonsquamous (HR, 0.76; 95% CI, 0.47-1.23) histologic type. Similar to OS, the addition of pembrolizumab prolonged PFS across all subgroups in the CPS greater than or equal to 1 and intention-to-treat populations. Conclusions and Relevance: The findings of this trial suggest that adding pembrolizumab to chemotherapy with or without bevacizumab improved OS across subgroups of patients with persistent, recurrent, or metastatic cervical cancer. Trial Registration: ClinicalTrials.gov Identifier: NCT03635567.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
LilyWalker308发布了新的文献求助40
3秒前
9秒前
yanweihome完成签到 ,获得积分10
10秒前
水北完成签到,获得积分10
10秒前
龙龙发布了新的文献求助10
16秒前
爱思考的小笨笨完成签到,获得积分10
17秒前
迷人啤酒完成签到,获得积分10
20秒前
单身的曲奇完成签到,获得积分10
33秒前
传统完成签到,获得积分10
47秒前
从容煜城完成签到,获得积分10
48秒前
思源的应助被科科科科采纳,获得30
55秒前
菠萝人爱吃菠萝完成签到,获得积分10
58秒前
完美世界的应助被wangch198201采纳,获得10
1分钟前
bkagyin的应助被洁净代云采纳,获得10
1分钟前
suge完成签到,获得积分10
1分钟前
哪块小饼干完成签到,获得积分10
1分钟前
dddj完成签到,获得积分10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
玛玛哈哈完成签到,获得积分10
1分钟前
英俊的铭的应助被朗吟涤采纳,获得10
1分钟前
从容飞雪完成签到,获得积分10
2分钟前
2分钟前
科科科科发布了新的文献求助30
2分钟前
大方碧完成签到,获得积分10
2分钟前
哭泣的成协完成签到,获得积分10
2分钟前
Akim的应助被小卡拉米采纳,获得10
2分钟前
2分钟前
我是老大的应助被科科科科采纳,获得10
2分钟前
2分钟前
小卡拉米发布了新的文献求助10
3分钟前
大意的之柔完成签到,获得积分10
3分钟前
CodeCraft的应助被欣喜寒烟采纳,获得10
3分钟前
小卡拉米完成签到,获得积分10
3分钟前
包容的初阳完成签到,获得积分10
3分钟前
深情安青的应助被荷兰香猪采纳,获得10
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
3分钟前
脑洞疼的应助被科研通管家采纳,获得10
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173073
求助须知:如何正确求助?哪些是违规求助? 9565519
关于积分的说明 21780424
捐赠科研通 7767139
什么是DOI,文献DOI怎么找? 3431536
关于科研通互助平台的介绍 2555638
邀请新用户注册赠送积分活动 2476675